E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Treatment of glabellar frown lines |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 10.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10052609 |
E.1.2 | Term | <Manually entered code. Term in E.1.1> |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of the study is to investigate the efficacy of NT 201 in the treatment of glabellar frown lines by assessing the proportion of responders at maximum frown at Day 28. A responder is thereby defined as a subject achieving an improvement of the FWS of at least one point from Baseline Visit to Day 28. |
|
E.2.2 | Secondary objectives of the trial |
Investigation of efficacy of NT 201 by assessing the percentage of responders at rest and at maximum frown at Days 28 and 84 by investigator’s rating according to the FWS. Evaluationv of the subject’s self assessment of the treatment success. Therefore, the percentage of responders with respect to the 4-point Patient’s Assessment Scale at rest and at maximum frown at Visit 3 (Day 28) and Visit 4 (Day 84) will be examined. A responder is defined as a subject with an improvement in the patient’s assessment of at least one point from Visit 2 (Day 0) to Visit 3 (Day 28) and Visit 4 (Day 84), respectively. Furthermore, the percentage of responders at rest and at maximum frown at Days 28 and 84 will be estimated by PGA of change in appearance of glabellar frown lines. Here, a responder has to achieve a score of at least +2 in the Patient’s Global Assessment Scale. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Moderate to severe glabellar frown lines at maximum frown as assessed by the investigator according to FWS 2. Age: between 18 and 65 years (inclusively) 3. Stable medical condition (assessed at Visit 2 and defined in the protocol) 4. Willing and able to complete the entire course of the trial and to comply with trial instructions 5. Written informed consent |
|
E.4 | Principal exclusion criteria |
1. Previous treatment with Botulinum toxin of any serotype in the upper third part of the face within the last 6 months 2. Previous treatment with biodegradable fillers in the glabellar area within the last 12 months 3. Previous insertion of permanent material in the glabellar area, including fat graft (regardless of the time between previous treatment and this study) 4. Previous treatment with any facial cosmetic procedure (e.g. chemical peeling, photo rejuvenation) in the glabellar area within the last 12 months 5. Any surgery in the glabellar area including surgical removal of the corrugator, procerus, or depressor supercilii muscles or a combination of these, or scars in the glabellar area 6. Any other planned cosmetic procedure in the upper third part of the face during the trial period 7. Inability to substantially lessen glabellar frown lines even by physically spreading them apart 8. Marked facial asymmetry or ptosis of eyelid and/or eyebrow 9. History of facial nerve palsy 10. Any infection in the area of the injection sites 11.Any medical condition that may put the subject at increased risk with exposure to NT 201, including diagnosed myasthenia gravis, Lambert-Eaton Syndrome, amyotrophic lateral sclerosis or any other disorder that might interfere with neuromuscular function 12. Bleeding disorders or intake of drugs in doses that will lead to an anticoagulative effect (e.g. heparin, cumarines, clopidogrel, non-steroidal anti-inflammatory drugs, acetylsalicylic acid) 10 days before injection 13. Intake of any of the forbidden concomitant medication, e. g. aminoglycoside antibiotics, or other agents that might interfere with neuromuscular function (e.g. D-penicillinamine, curarine-type muscle relaxants, succinylcholine) or might interfere with the action of Botulinum toxin (e.g. chloroquine) 14. Known allergy or sensitivity to the trial medication or its components 15. Pregnancy , nursing, or planning of pregnancy during the trial period, or no usage of appropriate methods of contraception (such as implants, injectables, combined oral contraceptives, some intrauterine devices, vasectomised partner) by females of childbearing potential 16. Evidence of recent alcohol or drug abuse 17. Psychiatric problems that, in the investigator’s opinion, are severe enough to interfere with trial results 18. Participation in another clinical trial within 30 days prior to screening
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Response to the treatment, defined as an improvement of the FWS at maximum frown as assessed by the investigator of at least one point from Visit 2 (Day 0) to Visit 3 (Day 28). The primary efficacy parameter is the expected proportion of responders. (A parametric 95% confidence interval will be estimated for the primary efficacy parameter.)
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Information not present in EudraCT |
E.6.2 | Prophylaxis | Information not present in EudraCT |
E.6.3 | Therapy | Information not present in EudraCT |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Information not present in EudraCT |
E.6.7 | Pharmacodynamic | Information not present in EudraCT |
E.6.8 | Bioequivalence | Information not present in EudraCT |
E.6.9 | Dose response | Information not present in EudraCT |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | Information not present in EudraCT |
E.6.12 | Pharmacoeconomic | Information not present in EudraCT |
E.6.13 | Others | Information not present in EudraCT |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Information not present in EudraCT |
E.7.1.1 | First administration to humans | Information not present in EudraCT |
E.7.1.2 | Bioequivalence study | Information not present in EudraCT |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Information not present in EudraCT |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | Information not present in EudraCT |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Information not present in EudraCT |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 4 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial months | 4 |